Aurora, Colorado
Phase 3 cancer trials in Aurora, CO
55 Phase 3 cancer studies are recruiting participants at sites in Aurora as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Aurora at a glance
- 55 studies are recruiting at a site in Aurora.
- By phase: Phase 2/3 (4), Phase 3 (51).
- By sponsor: industry (32), university, hospital or other (18), government (5).
- By research area: Breast Cancer (15), Lung Cancer (13), Prostate Cancer (11), Melanoma (9), Lymphoma (7).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Aurora
Basic details from each study's public record (the 30 most recently updated of 55). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UCHealth University of Colorado Hospital
- Registry record
- NCT06058377 · updated
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Phase 3
- Ages 18 to 60
- Female participants
- Sponsor
- NRG Oncology
- Study site
- UCHealth University of Colorado Hospital
- Registry record
- NCT05879926 · updated
E-Mindfulness Approaches for Living After Breast Cancer
- Phase 3
- Ages 18 to 50
- All sexes
- Sponsor
- NRG Oncology
- Study site
- UCHealth University of Colorado Hospital
- Registry record
- NCT06748222 · updated
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Phase 3
- Ages 60 and older
- All sexes
- Sponsor
- American Society of Clinical Oncology
- Study site
- University of Colorado Anschutz Medical Campus
- Registry record
- NCT06377852 · updated
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT06380751 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Aurora, CO on ClinicalTrials.gov.
Lung cancer studies recruiting in Aurora
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Registry record
- NCT06767514 · updated
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Colorado Anschutz Medical Campus ( Site 0151)
- Registry record
- NCT06623422 · updated
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Colorado Cancer Center ( Site 3268)
- Registry record
- NCT07513376 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Rocky Mountain Cancer Centers-Aurora · UCHealth University of Colorado Hospital
- Registry record
- NCT04267848 · updated
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study site
- Rocky Mountain Cancer Centers LLP
- Registry record
- NCT07144280 · updated
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Rocky Mountain Cancer Centers-Aurora
- Registry record
- NCT04181060 · updated
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- ArriVent BioPharma, Inc.
- Study site
- University of Colorado Health
- Registry record
- NCT07185997 · updated
Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Vergent Bioscience, Inc.
- Study site
- University of Colorado Hospital
- Registry record
- NCT07499674 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Aurora, CO on ClinicalTrials.gov.
Prostate cancer studies recruiting in Aurora
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- BioNTech SE
- Study site
- Rocky Mountain Cancer Centers
- Registry record
- NCT07365995 · updated
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Anschutz Cancer Pavilion ( Site 0046)
- Registry record
- NCT06136624 · updated
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Rocky Mountain Regional VA Medical Center
- Registry record
- NCT06931340 · updated
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Janssen Research & Development, LLC
- Study sites
- Rocky Mountain Cancer Centers · University of Colorado Cancer Center
- Registry record
- NCT07164443 · updated
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- UCHealth University of Colorado Hospital
- Registry record
- NCT07200830 · updated
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Rocky Mountain Cancer Centers
- Registry record
- NCT07225946 · updated
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Rocky Mountain Regional Veterans Affairs Medical Center ( Site 0053)
- Registry record
- NCT06925737 · updated
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- NRG Oncology
- Study site
- UCHealth University of Colorado Hospital
- Registry record
- NCT05946213 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Aurora, CO on ClinicalTrials.gov.
Melanoma studies recruiting in Aurora
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Phase 3
- Ages 75 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study site
- UCHealth University of Colorado Hospital
- Registry record
- NCT07068074 · updated
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study sites
- Rocky Mountain Regional VA Medical Center · University of Colorado Cancer Center
- Registry record
- NCT06246916 · updated
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immatics US, Inc.
- Study site
- University of Colorado, Anschutz Medical Campus
- Registry record
- NCT06743126 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Aurora, CO on ClinicalTrials.gov.
Lymphoma studies recruiting in Aurora
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- UCHealth University of Colorado Hospital
- Registry record
- NCT06337318 · updated
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Nuvation Bio Inc.
- Study site
- University of Colorado Health Cancer Care
- Registry record
- NCT05303519 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Children's Hospital Colorado · UCHealth University of Colorado Hospital
- Registry record
- NCT05675410 · updated
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- BeOne Medicines
- Study site
- Rocky Mountain Cancer Centers (Williams) Usor
- Registry record
- NCT06846671 · updated
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Lyell Immunopharma, Inc.
- Study site
- University of Colorado
- Registry record
- NCT07188558 · updated
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- BeOne Medicines
- Study site
- Rocky Mountain Cancer Centers (Williams) Usor
- Registry record
- NCT06943872 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Aurora, CO on ClinicalTrials.gov.
Ask about studies near Aurora
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.
Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections